Engineering Biology to End Disease - Persephone Biosciences

Persephone Biosciences is a biotechnology company challenging the status quo of medicine to develop innovative products that positively impact health and well-being for all.

PLATFORM

We combine artificial intelligence with real-world data to establish a new paradigm in microbiome drug development.

REAL–WORLD DATA (RWD): MULTI–OMIC ANALYSES MAP GUT–IMMUNE AXIS

MACHINE–LEARNING:
IDENTIFIES THE "DRUGGABLE" MICROBIOME

RWD AI–DRIVEN THERAPIES:
AI MODELS PREDICT THERAPIES AND MARKERS

REAL–WORLD DATA

Scalable biospecimen collection through community and hospital-based programs.

STEPHANIE CULLER, PhD

STEVE VAN DIEN, PhD

PAUL GRINT, MD

MEET THE TEAM

Co-Founder and CEO

Co-Founder and CTO

Persephone Board of Director

Poop for the cure® is an IRB-approved study that acquires thousands of stool samples and detailed real-world data (RWD) from anyone with disease nationwide to drive machine learning approaches towards the broad mapping of healthy and disease populations.

Patient cohorts and observational longitudinal clinical studies are carefully designed to provide validated data to drive therapeutic and biomarker development. Biospecimens are collected through collaborations with leading academic researchers and CRO’s nationwide.

OBSERVATIONAL CLINICAL STUDIES

To profile the gut-immune axis we design longitudinal clinical studies with access to electronic health records (EHR) and collect stool (microbiome) and blood (immune) samples from thousands of healthy and diseased patients nationwide.

We analyze DNA, RNA, proteins and metabolite data from multi-omics analyses on patient samples as these are factors that significantly impact the immune system.

Machine learning (artificial intelligence- AI) models are trained on information provided in patient EHRs and multi-omics datasets from patient samples to decode the complex interactions between the gut microbiome and the human immune system.

The resulting AI models predict de novo the “druggable” portion of the microbiome, therapeutic interventions and biomarkers.

AI-derived therapies target the “druggable” portion of the diseased microbiome. AI models predict biomarkers relevant for patient stratification and novel drug targets. Therapies consist of single fermented gut bacteria to be delivered orally.

Manufacturing is scalable (Persephone team has commercial manufacturing experience scaling).

INDUSTRY FIRST

ENGINEERING BIOLOGY TO END DISEASE

LEARN MORE LEARN MORE Read Bio Read Bio Read Bio

Johnson & Johnson Innovation and BARDA Announce First Cohort of Companies as Part of Its BLUE KNIGHT™ Collaboration

We are honored to be selected for the 2020 BIO Investor Forum Digital Buzz of BIO Contest, recognizing U.S. based companies with groundbreaking, early stage technologies with the potential for improving our lives.

LEARN MORE VOTE HERE!

Engineering Biology to End Diseasepersephone2020-08-09T02:43:29+00:00

TELEVISION

CNBC’s Advancements TV with Ted Danson

Developing a COVID-19 Therapeutic: Interview with Stephanie Culler CEO and co-founder of Persephone Biosciences

INTERVIEW

Microbiome For Mars 2020:
Persephone Biosciences

TECHNOLOGY

Collaboration with Curebase on CURE-19 Featured on Geneonline

PARTNERSHIP

Recent Press

In The News

TEDx San Diego

Designing Microbiome Therapeutics to Help Cure Cancer

SDBN BUZZ Podcast: Does the Gut Microbiome Affect the Response to Immuno-Therapy?

PODCAST 2019

2019 Biocom Catalyst Award Winners

AWARD

Key to New Cancer Treatments

SMITHSONIAN 2019

Recent Press

In The News